OBJECTIVE: To identify differences in the management and outcome of patients with central nervous system metastases from epithelial ovarian cancer. METHODS: The clinical and pathologic characteristics, treatment, and outcome of 23 patients with brain metastases from epithelial ovarian cancer who were treated during 1982-1994 were compared with those of 20 patients treated during 1995-2010 at the same center. RESULTS: No differences were found in terms of primary tumor characteristics, time interval from ovarian cancer diagnosis to brain involvement diagnosis, sites of metastasis, and presence of extracranial disease. The main difference between the 2 groups was the therapeutic approach. During 1982-1994, most patients received radiotherapy only, whereas most patients during 1995-2010 underwent surgical resection followed by radiotherapy and/or chemotherapy. The duration of survival during 1982-1994 was 5 months, which was significantly shorter than the duration of survival (18 months) during 1995-2010. CONCLUSION: An aggressive multimodal treatment approach might prolong the survival of patients with brain involvement from ovarian cancer.
OBJECTIVE: To identify differences in the management and outcome of patients with central nervous system metastases from epithelial ovarian cancer. METHODS: The clinical and pathologic characteristics, treatment, and outcome of 23 patients with brain metastases from epithelial ovarian cancer who were treated during 1982-1994 were compared with those of 20 patients treated during 1995-2010 at the same center. RESULTS: No differences were found in terms of primary tumor characteristics, time interval from ovarian cancer diagnosis to brain involvement diagnosis, sites of metastasis, and presence of extracranial disease. The main difference between the 2 groups was the therapeutic approach. During 1982-1994, most patients received radiotherapy only, whereas most patients during 1995-2010 underwent surgical resection followed by radiotherapy and/or chemotherapy. The duration of survival during 1982-1994 was 5 months, which was significantly shorter than the duration of survival (18 months) during 1995-2010. CONCLUSION: An aggressive multimodal treatment approach might prolong the survival of patients with brain involvement from ovarian cancer.
Authors: Laura M Divine; Nora T Kizer; Andrea R Hagemann; Meredith E Pittman; Ling Chen; Matthew A Powell; David G Mutch; Janet S Rader; Premal H Thaker Journal: Gynecol Oncol Date: 2016-05-08 Impact factor: 5.482
Authors: Madiha A Gilani; Noelle L Williams; Carolyn Giordano; Norman Rosenblum; Wenyin Shi; Pramila Anne; Russell J Schilder Journal: Open J Obstet Gynecol Date: 2016-08-15
Authors: Alexandre André Balieiro Anastácio da Costa; Elizabeth Santana Dos Santos; Deborah Porto Cotrim; Natasha Carvalho Pandolfi; Marcelle Goldner Cesca; Henrique Mantoan; Solange Moraes Sanches; Adriana Regina Gonçalves Ribeiro; Louise de Brot; Graziele Bonvolim; Paulo Issamu Sanematsu; Ronaldo Pereira de Souza; Joyce Maria Lisboa Maya; Fabrício de Souza Castro; João Paulo da Nogueira Silveira Lima; Michael Jenwel Chen; Andrea Paiva Gadelha Guimarães; Glauco Baiocchi Journal: BMC Cancer Date: 2019-12-05 Impact factor: 4.430